Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending June 12, 2008. The report details a specific corporate action regarding the repurchase and cancellation of the company's own ordinary shares, executed under authority granted by shareholders at the Annual General Meeting on May 21, 2008.
Key Financial Metrics
The filing does not provide comprehensive financial statements such as revenue, profit, cash flow, margins, or debt levels. The only financial data disclosed relates to the share buyback transaction:
- Shares Purchased: 1,650,000 Ordinary shares of 25 pence each.
- Purchase Date: June 12, 2008.
- Purchase Price: 1,065.23 pence per share.
- Treasury Shares Held: 484,194,158 shares (representing 9.10% of total voting rights).
- Shares in Issue: 5,322,495,445 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the company's share capital through the cancellation of 1,650,000 repurchased shares. Consequently, the number of shares held in Treasury has been updated to reflect this transaction. No other material changes to operations or financial position are disclosed in this specific filing.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It is a compliance announcement confirming adherence to the Financial Services Authority's Disclosure and Transparency Rules regarding the share repurchase.
Key Facts for Investor Verification
- Verify the total cost of the buyback by multiplying 1,650,000 shares by the price of 1,065.23 pence.
- Confirm the updated total voting rights denominator (5,322,495,445 shares) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Note that the repurchased shares were cancelled rather than held indefinitely in Treasury, reducing the total issued share count.
- Recognize that this filing does not contain quarterly or annual financial performance data.